Xoma | XOMA - Des Atouts



Des Atouts Changement Date
AbbVie USD 135.12B 1.35B 2026-06
Agenus USD 172.69M 13.76M 2026-06
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Ardelyx USD 504.51M 2.9M 2026-03
aTyr Pharma USD 69.82M 9.83M 2026-06
BioMarin Pharmaceutical USD 11.72B 3.13B 2026-06
Celldex Therapeutics USD 782.35M 271.09M 2026-06
Curis USD 29.69M 9.72M 2026-03
Eli Lilly USD 142.28B 25.71B 2026-06
Emergent BioSolutions USD 1.82B 69.9M 2023-12
Incyte USD 7.87B 533.53M 2026-06
MacroGenics USD 345.41M 127.54M 2026-06
Novartis USD 122.03B 3.5B 2026-06
Novartis USD 118.53B 7.58B 2026-03
Pfizer USD 201.13B 6.49B 2026-06
Prothena USD 302.58M 47.32M 2026-06
Regeneron Pharmaceuticals USD 41.73B 861.8M 2026-06